Technology Bundle ID: TAB-2655

Small Interfering RNA Inhibition of Cannabanoid-1 Receptor (CB1R) for Treating Type 2 Diabetes

Request More Info
Licensing Contact:
Primary Inventors: 
George Kunos (NIAAA)
Co-Inventors: 
Michael Czech (University of Massachusetts Medical School), Myriam Aouadi (University of Massachusetts Medical School), Tony Jourdan (NIAAA)
Application: 
Therapeutics
Development Status: 

In vivo data available (animal)

Institute or Center: 
NIAAA

The invention pertains to the use of glucan encapsulated non-immunostimulatory small interfering RNAs (siRNAs) to treat type-2 diabetes. Endocannabinoids (EC) are lipid signaling molecules that act on the same cannabinoid receptors that recognize and mediate the effects of endo- and phytocannabanoids. EC receptor CB1R activation is implicated in the development of obesity and its metabolic consequences, including insulin resistance and type 2 diabetes. Beta-cell loss has been demonstrated in a Zucker diabetic fatty (ZDF) rat model of type-2 diabetes through CB1R-mediated activation of a macrophage-mediated inflammatory response. Conversely, rats treated with a peripheral CB1R antagonist restores normoglycemia and preserves beta-cell function. Similar results are seen following selective in vivo knockdown of macrophage CB1R by daily treatment of ZDF rats with the instant D-glucan-encapsulated CB1R Small interfering RNA (siRNA). Knock-down of CB1R with using glucan encapsulated siRNA may represent a new commecializable method of treating type-2 diabetes or preventing the progression of insulin resistance to overt diabetes.

Applications:

    Treatment of obesity, insulin resistance, and diabetes.

Advantages:

    A new means of inhibiting the endocannabinoid receptor CB1R.

Patents

PCT Application PCT/US2014/043924
Filed on 2014-06-24
US Application 61/839,239
Filed on 2013-06-25
US Pat 10,077,446

Issued 2018-09-18

European Patent Application pending

Updated

Sep 19, 2013

Data Source: 
tts